RedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme Court

Core Viewpoint - RedHill Biopharma has been awarded approximately $8 million in a summary judgment by the New York Supreme Court in its legal proceedings against Kukbo Co. Ltd, with the court dismissing all of Kukbo's counterclaims and ruling in favor of RedHill's good faith commitment to the agreements [1][2]. Group 1: Legal Proceedings - The judgment includes $6.5 million plus approximately $1.5 million in interest, along with costs [1]. - The case stems from Kukbo's failure to make agreed payments to RedHill under a Subscription Agreement and an Exclusive License Agreement [2]. - RedHill intends to pursue its attorneys' fees and collection of the judgment, while Kukbo has the right to seek an appeal [3]. Group 2: Company Overview - RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on the commercialization and development of drugs for gastrointestinal diseases, infectious diseases, and oncology [4]. - The company promotes Talicia®, a drug for treating Helicobacter pylori infection in adults [4]. - Key clinical late-stage development programs include opaganib, RHB-107, RHB-102, RHB-104, and RHB-204, targeting various diseases and conditions [4].